Goldline Pharmaceutical Limited IPO

Goldline Pharmaceutical Ltd operates in the pharmaceutical marketing and distribution segment with an asset-light business model focused on outsourced manufacturing and branded product marketing.

The company offers products across several divisions including Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, catering to specialties such as cardiology, diabetology, orthopedics, pediatrics, gastroenterology, critical care, and wellness support.

The company does not own manufacturing facilities and instead partners with third-party manufacturers for production based on its formulations and market requirements. Products are sold through a network of distributors, retailers, wholesalers, hospitals, and healthcare providers across multiple Indian states including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.

The IPO is a book-built SME issue of approximately Rs 11.61 Cr with a price band of Rs 41–43 per share, implying a post-issue market cap of around Rs 41.28 Cr.

The issue consists entirely of a fresh issue of shares. The company plans to utilise IPO proceeds primarily for repayment or prepayment of certain borrowings and for general corporate purposes.

At the upper band, the IPO is valued at a P/E of around 13.93x post-issue earnings. Key strengths include an asset-light business model, diversified product portfolio, and established distribution network, while key risks include dependence on third-party manufacturers and relatively high debt levels.